(NASDAQ: VTVT) Vtv Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.81%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 35.93%.
Vtv Therapeutics's earnings in 2026 is -$26,974,000.On average, 7 Wall Street analysts forecast VTVT's earnings for 2026 to be -$16,005,508, with the lowest VTVT earnings forecast at -$25,243,621, and the highest VTVT earnings forecast at -$5,293,551. On average, 7 Wall Street analysts forecast VTVT's earnings for 2027 to be -$18,552,636, with the lowest VTVT earnings forecast at -$34,623,132, and the highest VTVT earnings forecast at -$12,489,472.
In 2028, VTVT is forecast to generate -$12,735,244 in earnings, with the lowest earnings forecast at -$14,590,350 and the highest earnings forecast at -$10,587,102.